Genomic architecture of lung cancersFernandez-Cuesta, Lynnette; McKay, James D. Erratum In Figure 1 on page 53 of Volume 28, Issue 1, BRAS (in the Adenocarcinoma circle) should in fact be KRAS and ASMS1 (in the Small-cell carcinoma circle) should in fact be ALMS1  . Current Opinion in Oncology. 28(2):192, March 2016. Current Opinion in Oncology: January 2016 - Volume 28 - Issue 1 - p 52–57 doi: 10.1097/CCO.0000000000000251 CANCER BIOLOGY: Edited by Pierre Hainaut and Amelie Plymoth Buy Erratum Abstract Author InformationAuthors Article MetricsMetrics Purpose of review Lung cancer remains the most frequent cancer worldwide and the leading cause of cancer death in most countries. The molecular characteristics of lung tumors play an important role in clinical decisions, which ultimately affect patients’ survival. This review aims to summarize the most recent genomic discoveries made on lung cancer. Recent findings A relatively comprehensive molecular characterization has been achieved for the three major types of lung cancer: adenocarcinoma, squamous-cell carcinoma, and small-cell carcinoma. Little is still known about large-cell neuroendocrine carcinoma and carcinoid tumors. A major finding has been the nonnegligible inter and intratumor heterogeneity of lung cancer and their impact in the clinical management of this disease. Summary The high load of mutations, the frequent inactivation of major tumor suppressor genes, and the huge heterogeneity of lung cancer tumors may complicate long-lasting therapeutic responses. The development of strategies for the early detection of lung cancer might translate into an increase of the number of surgical resectable tumors, and therefore contribute to improve the survival rate of these patients. Group of Genetic Cancer Susceptibility, Section of Genetics, International Agency for Research on Cancer (IARC-WHO), Lyon, France Correspondence to Lynnette Fernandez-Cuesta, International Agency for Research on Cancer, 150 Cours Albert Thomas, 69008 Lyon, France. Tel: +33 0 4 72 73 85 84; e-mail: firstname.lastname@example.org Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.